Shopping Cart 0
Cart Subtotal
USD 0

Max Delbruck Center for Molecular Medicine - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Max Delbruck Center for Molecular Medicine (MDC) is a biomedical research center that offers translating discoveries from molecular research into applications. The company's research area services offer for cancer research, cardiovascular and metabolic disease, diseases of the nervous system, medical systems biology and clinical research. Its labs and fellows include research labs and fellows. MDC research labs offer biochemistry and proteomics, cancer, cardiovascular research, cell biology, computational biology, developmental biology, epidemiology and gene engineering. The company's scientific infrastructure offers technology platforms, technology transfer, support services and animal facilities. MDC is headquartered in Berlin, Germany.

Max Delbruck Center for Molecular Medicine-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 11

Licensing Agreements 13

Fate Therapeutics Enters into Option and Licensing Agreement with Max Delbruck Center 13

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 14

Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 15

Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 16

Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 17

Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 18

Max Delbruck Center for Molecular Medicine-Key Competitors 19

Max Delbruck Center for Molecular Medicine-Key Employees 20

Max Delbruck Center for Molecular Medicine-Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Government and Public Interest 22

Dec 13, 2017: Molecular Chaperones Shown to Assist in the Fight against Huntington Disease 22

Product News 24

Jul 25, 2017: BeLOVE launches: first patients recruited for large study in Germany's capital city of Berlin 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Key Facts 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Max Delbruck Center for Molecular Medicine, Deals By Therapy Area, 2012 to YTD 2018 8

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 11

Fate Therapeutics Enters into Option and Licensing Agreement with Max Delbruck Center 13

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 14

Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 15

Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 16

Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 17

Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 18

Max Delbruck Center for Molecular Medicine, Key Competitors 19

Max Delbruck Center for Molecular Medicine, Key Employees 20

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Max Delbruck Center for Molecular Medicine, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Max Delbruck Center for Molecular Medicine (MDC) is a biomedical research center that offers translating discoveries from molecular research into applications. The company's research area services offer for cancer research, cardiovascular and metabolic disease, diseases of the nervous system, medical systems biology and clinical research. Its labs and fellows include research labs and fellows. MDC research labs offer biochemistry and proteomics, cancer, cardiovascular research, cell biology, computational biology, developmental biology, epidemiology and gene engineering. The company's scientific infrastructure offers technology platforms, technology transfer, support services and animal facilities. MDC is headquartered in Berlin, Germany.

Max Delbruck Center for Molecular Medicine-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 11

Licensing Agreements 13

Fate Therapeutics Enters into Option and Licensing Agreement with Max Delbruck Center 13

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 14

Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 15

Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 16

Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 17

Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 18

Max Delbruck Center for Molecular Medicine-Key Competitors 19

Max Delbruck Center for Molecular Medicine-Key Employees 20

Max Delbruck Center for Molecular Medicine-Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Government and Public Interest 22

Dec 13, 2017: Molecular Chaperones Shown to Assist in the Fight against Huntington Disease 22

Product News 24

Jul 25, 2017: BeLOVE launches: first patients recruited for large study in Germany's capital city of Berlin 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Key Facts 2

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Max Delbruck Center for Molecular Medicine, Deals By Therapy Area, 2012 to YTD 2018 8

Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 11

Fate Therapeutics Enters into Option and Licensing Agreement with Max Delbruck Center 13

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 14

Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 15

Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 16

Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 17

Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 18

Max Delbruck Center for Molecular Medicine, Key Competitors 19

Max Delbruck Center for Molecular Medicine, Key Employees 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Max Delbruck Center for Molecular Medicine, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.